Comparative Pharmacology
Head-to-head clinical analysis: MAGNACORT versus OTICAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNACORT versus OTICAIR.
MAGNACORT vs OTICAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid receptor agonist; modulates gene transcription to produce anti-inflammatory and immunosuppressive effects.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication; fluocinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, reducing prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
5 mg orally once daily for 7 days, then 5 mg orally every other day for 7 days. Alternatively, 1 mg/kg intravenously every 12 hours for 14 days.
1-2 sprays into each affected ear twice daily for 7 days. Topical route.
None Documented
None Documented
3.5 ± 0.8 hours (terminal); prolonged in renal impairment (up to 12 hours in ESRD) and hepatic disease; requires dose adjustment in CrCl <30 mL/min
4.2 hours; prolonged in renal impairment (up to 12 hours in creatinine clearance <30 mL/min)
Renal (80% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion); biliary/fecal (15%)
Renal: 85% unchanged; biliary/fecal: 10%
Category C
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid